Clicky

Novo Nordisk A/S(NOVO-B)

Description: Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.


Keywords: Medicine Biopharmaceutical Clinical Medicine Life Sciences Pharmaceutical Products Diabetes Obesity Chronic Disease Insulin Peptide Hormones Recombinant Proteins Growth Hormone Therapy Haemophilia Anti Diabetic Medication Glp 1 Related Delivery Systems Hormone Replacement Therapy Novo Nordisk Growth Disorders Obesity Care Oral Antidiabetic Products

Home Page: www.novonordisk.com

Novo Allé 1
Bagsvaerd, 2880
Denmark
Phone: 45 44 44 88 88


Officers

Name Title
Mr. Lars Fruergaard Jorgensen Pres, CEO & Member of Management Board
Mr. Karsten Munk Knudsen Exec. VP, CFO & Member of the Management Board
Mr. Henrik Ehlers Wulff Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board
Ms. Camilla Sylvest Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board
Dr. Martin Holst Lange Exec. VP, Head of Devel. & Member of the Management Board
Ms. Monique Carter Exec. VP, Head of People & Organisation and Member of Management Board
Dr. Marcus Schindler Ph.D. EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board
Mr. Maziar Mike Doustdar Exec. VP, Head of International Operations & Member of the Management Board
Mr. Douglas J. Langa Exec. VP, Head of North America Operations & Member of Management Board
Mr. Ludovic Helfgott Exec. VP, Head of Rare Disease & Member of Management Board

Exchange: CO

Country: DK

Currency: Danish krone (kr)

Forward PE: 30.7692
Trailing PE: 39.4176
Price-to-Book MRQ: 27.5149
Price-to-Sales TTM: 12.1582
IPO Date:
Fiscal Year End: December
Full Time Employees: 52696
Back to stocks